Literature DB >> 21807978

First description of an RND-type multidrug efflux pump in Achromobacter xylosoxidans, AxyABM.

Julien Bador1, Lucie Amoureux, Jean-Marie Duez, Anthony Drabowicz, Eliane Siebor, Catherine Llanes, Catherine Neuwirth.   

Abstract

Achromobacter xylosoxidans is an emerging pathogen in cystic fibrosis patients. The multidrug resistance of these bacteria remains poorly understood. We have characterized in a clinical strain the first resistance-nodulation-cell division (RND)-type multidrug efflux pump in this species: AxyABM. The inactivation of the transporter component axyB gene led to decreased MICs of cephalosporins (except cefepime), aztreonam, nalidixic acid, fluoroquinolones, and chloramphenicol.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21807978      PMCID： PMC3186983          DOI： 10.1128/AAC.00341-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

Review 1.  Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms.

Authors:  K Poole
Journal:  J Mol Microbiol Biotechnol       Date:  2001-04

2.  Detection of a variant metallo-beta-lactamase, IMP-10, from two unrelated strains of Pseudomonas aeruginosa and an alcaligenes xylosoxidans strain.

Authors:  Shizuko Iyobe; Haruko Kusadokoro; Ayako Takahashi; Sachie Yomoda; Toyoji Okubo; Akio Nakamura; Koji O'Hara
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

3.  Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis.

Authors:  L Saiman; Y Chen; S Tabibi; P San Gabriel; J Zhou; Z Liu; L Lai; S Whittier
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

4.  In70 of plasmid pAX22, a bla(VIM-1)-containing integron carrying a new aminoglycoside phosphotransferase gene cassette.

Authors:  M L Riccio; L Pallecchi; R Fontana; G M Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

5.  Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa.

Authors:  N Masuda; E Sakagawa; S Ohya; N Gotoh; H Tsujimoto; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

Review 6.  Multidrug efflux in Pseudomonas aeruginosa: components, mechanisms and clinical significance.

Authors:  K Poole; R Srikumar
Journal:  Curr Top Med Chem       Date:  2001-05       Impact factor: 3.295

7.  PCR typing of genetic determinants for metallo-beta-lactamases and integrases carried by gram-negative bacteria isolated in Japan, with focus on the class 3 integron.

Authors:  Naohiro Shibata; Yohei Doi; Kunikazu Yamane; Tetsuya Yagi; Hiroshi Kurokawa; Keigo Shibayama; Haru Kato; Kumiko Kai; Yoshichika Arakawa
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

8.  Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients.

Authors:  C R Hansen; T Pressler; K G Nielsen; P Ø Jensen; T Bjarnsholt; N Høiby
Journal:  J Cyst Fibros       Date:  2009-11-25       Impact factor: 5.482

9.  Identification and characterization of the emhABC efflux system for polycyclic aromatic hydrocarbons in Pseudomonas fluorescens cLP6a.

Authors:  Elizabeth M Hearn; Jonathan J Dennis; Murray R Gray; Julia M Foght
Journal:  J Bacteriol       Date:  2003-11       Impact factor: 3.490

10.  Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005.

Authors:  Samiya Razvi; Lynne Quittell; Ase Sewall; Hebe Quinton; Bruce Marshall; Lisa Saiman
Journal:  Chest       Date:  2009-06-08       Impact factor: 9.410
View more
  31 in total

1.  AcGI1, a novel genomic island carrying antibiotic resistance integron In687 in multidrug resistant Achromobacter xylosoxidans in a teaching hospital in Thailand.

Authors:  Pisut Pongchaikul; Pitak Santanirand; Svetlana Antonyuk; Craig Winstanley; Alistair C Darby
Journal:  FEMS Microbiol Lett       Date:  2020-07-01       Impact factor: 2.742

Review 2.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

3.  Achromobacter xylosoxidans Cellular Pathology Is Correlated with Activation of a Type III Secretion System.

Authors:  Adam M Pickrum; Orlando DeLeon; Aaron Dirck; Maxx H Tessmer; Molly O Riegert; Julie A Biller; Nathan A Ledeboer; John R Kirby; Dara W Frank
Journal:  Infect Immun       Date:  2020-06-22       Impact factor: 3.441

4.  Achromobacter xylosoxidans Bacteremia and Cellulitis: A Report of a Case.

Authors:  Julia Dai; Auris O Huen; Lori A Kestenbaum; Margaret D Sarezky; Carrie C Coughlin; Albert C Yan
Journal:  Pediatr Dermatol       Date:  2015-05-14       Impact factor: 1.588

5.  Role of AxyZ Transcriptional Regulator in Overproduction of AxyXY-OprZ Multidrug Efflux System in Achromobacter Species Mutants Selected by Tobramycin.

Authors:  Julien Bador; Catherine Neuwirth; Nadège Grangier; Marie Muniz; Leslie Germé; Jérémy Bonnet; Vignesh-Guru Pillay; Catherine Llanes; Claire de Curraize; Lucie Amoureux
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

6.  Genomic insights into intrinsic and acquired drug resistance mechanisms in Achromobacter xylosoxidans.

Authors:  Yongfei Hu; Yuying Zhu; Yanan Ma; Fei Liu; Na Lu; Xi Yang; Chunguang Luan; Yong Yi; Baoli Zhu
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

7.  Detection of Achromobacter xylosoxidans in hospital, domestic, and outdoor environmental samples and comparison with human clinical isolates.

Authors:  Lucie Amoureux; Julien Bador; Sakina Fardeheb; Cédric Mabille; Charlyne Couchot; Clémence Massip; Anne-Lise Salignon; Guillaume Berlie; Véronique Varin; Catherine Neuwirth
Journal:  Appl Environ Microbiol       Date:  2013-09-13       Impact factor: 4.792

Review 8.  Achromobacter Infections and Treatment Options.

Authors:  Burcu Isler; Timothy J Kidd; Adam G Stewart; Patrick Harris; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

9.  Innate aminoglycoside resistance of Achromobacter xylosoxidans is due to AxyXY-OprZ, an RND-type multidrug efflux pump.

Authors:  Julien Bador; Lucie Amoureux; Emmanuel Blanc; Catherine Neuwirth
Journal:  Antimicrob Agents Chemother       Date:  2012-10-22       Impact factor: 5.191

Review 10.  Achromobacter xylosoxidans and Stenotrophomonas maltophilia: Emerging Pathogens Well-Armed for Life in the Cystic Fibrosis Patients' Lung.

Authors:  Quentin Menetrey; Pauline Sorlin; Estelle Jumas-Bilak; Raphaël Chiron; Chloé Dupont; Hélène Marchandin
Journal:  Genes (Basel)       Date:  2021-04-21       Impact factor: 4.096
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.